London, United Kingdom
Pear Bio, founded in 2017 and headquartered in the United Kingdom, is making strides in the fields of Biotechnology and Health Care with its focus on Patient-centered cancer precision medicine. The company employs a proprietary computational biology platform to unravel intricate cancer biology, facilitating both patient-centric functional precision medicine and drug discovery.
At the heart of Pear Bio's innovation is its unique use of microphysiological systems and 3D computer vision. By culturing patient tumor samples into 3D immune-microtumors and employing a cutting-edge computer vision/DL pipeline, the company can predict the likely efficacy of various treatment options tailored to each patient's needs. Moreover, their multi-omics pipeline is instrumental in identifying novel targets for non-responsive patients, feeding directly into their in-house drug discovery efforts.
The company recently secured a Series A investment on 22 August 2023, with backing from Wavemaker 360, highlighting confidence in its ability to innovate in this critical sector.
